Key result
Percutaneous trans-axilla TAVR achieved a 100% device success rate with no 30-day major adverse events, demonstrating feasibility and safety for patients ineligible for transfemoral access.
Why the study?
The left axillary artery is an attractive alternative access route for TAVR, but concerns remain regarding vascular complications, lack of compressibility, and thorax-related complications.
Observational (n=13)
No
Percutaneous trans-axilla TAVR is a feasible and safe alternative access route that may mitigate thorax-related complications for patients with severe aortic stenosis ineligible for transfemoral access.
Answers are grounded in this paper and cite their sources.
May offer an alternative for transfemoral-ineligible TAVR patients; leaves open need for larger comparative studies.
The left axillary artery is an attractive alternative access route for transcatheter aortic valve replacement (TAVR) and may provide better outcomes compared to other alternatives. Nevertheless, there remain concerns about vascular complications, lack of compressibility, and thorax-related complications. Between March 2019 and March 2021, 13 patients underwent transaxillary TAVR for severe aortic stenosis at the University Hospital Bonn. The puncture was performed with a puncture at the distal segment of the axillary artery through the axilla, with additional femoral access for applying a safety wire inside the axillary artery. Device success was defined according to the VARC 2 criteria. The study participants were advanced in age (77 ± 9 years old), and 54% were female, with an intermediate risk for surgery (STS risk score 4.7 ± 2.0%). The average diameter of the distal segment of the axillary artery was 5.8 ± 1.0 mm (i.e., the puncture site) and 7.6 ± 0.9 mm for the proximal axillary artery. Device success was achieved in all patients. 30-day major adverse cardiac and cerebrovascular events were 0%. With complete percutaneous management, stent-graft implantation was performed at the puncture site in 38.5% of patients. Minor bleeding was successfully managed with manual compression. Moreover, no thorax-related complications, hematomas, or nerve injuries were observed. Percutaneous trans-axilla TAVR was found to be feasible and safe. This modified approach may mitigate the risk of bleeding and serious complications in the thorax and be less invasive than surgical alternatives.
No takes yet. Share an insight, caveat, or question.
Sugiura et al. (2022) conducted an observational in Severe aortic stenosis (n=13). Percutaneous trans-axilla transcatheter aortic valve replacement was evaluated on Device success. Percutaneous trans-axilla TAVR achieved a 100% device success rate with no 30-day major adverse events, demonstrating feasibility and safety for patients ineligible for transfemoral access.
Synapse has enriched 10 related papers. Consider them for comparative context: